View Older Stories
-
RBC Capital Upgrades Vertex (VRTX) to Outperform
-
Biotech stocks: Q3 earnings preview
-
Vertex (VRTX) PT Raised to $423 at RBC Capital
-
Vertex (VRTX) PT Lowered to $405 at RBC Capital Amid Setbacks
-
Vertex (VRTX) PT Lowered to $420 at RBC Capital
-
RBC Capital weighs in on Vertex (VRTX) following IgAN competitor data
-
Vertex (VRTX) PT Raised to $420 at RBC Capital; 'Alyftrek Could Be Off To a Good Start'
-
Vertex (VRTX) PT Raised to $408 at RBC Capital
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Vertex (VRTX) PT Raised to $401 at RBC Capital; 'We Would Look for a More Compelling Entry Point'
-
Vertex (VRTX) PT Raised to $451 at RBC Capital
-
Vertex (VRTX) PT Raised to $437 at RBC Capital
-
Vertex (VRTX) PT Lowered to $421 at RBC Capital
-
Vertex (VRTX) PT Raised to $424 at RBC Capital
-
Vertex (VRTX) PT Raised to $265 at RBC Capital, Following Clinical Business Update
-
CRISPR Therapeutics' (CRSP) Restructured Vertex (VRTX) Deal 'Fantastic', Analyst Says
-
Vertex (VRTX) Risk/Reward Looks Attractive Heading into Potentially Imminent ’864 AAT Data - RBC Capital
-
Vertex (VRTX) Site Data Indicates '864 Safety Could be Derisked in February - RBC Capital
-
UPDATE: RBC Capital Upgrades Vertex (VRTX) to Outperform
-
RBC Capital Downgrades Vertex (VRTX) to Sector Perform
-
Vertex (VRTX) PT Raised to $235 at RBC Capital
-
Vertex (VRTX) Clinicaltrials.gov Update Could Be Important For CF Life Cycle - RBC
-
Vertex (VRTX) PT Raised to $213 at RBC Capital
-
Vertex (VRTX) PT Lowered to $214 at RBC Capital
-
Vertex (VRTX) PT Lowered to $213 at RBC Capital
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Vertex (VRTX) PT Lowered to $204 at RBC Capital
-
Vertex (VRTX) Gets Reimbursement in Australia - RBC
-
Vertex (VRTX) PT Raised to $203 at RBC Capital
-
Major Overhang Lifted for Vertex Pharma (VRTX) - RBC
-
Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC
-
Vertex (VRTX) PT Raised to $202 at RBC Capital
-
Vertex (VRTX) PT Raised to $181 at RBC Capital Citing Potential For Triple Early Approval
-
RBC Capital Starts Vertex (VRTX) at Outperform
-
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
-
Biotech Seen Grinding Higher, Says RBC Capital (IBB)
-
Vertex (VRTX) Seen as Top Large-Cap Biotech Growth Idea at RBC
-
Vertex Pharma. (VRTX) Remains Top Pick at RBC Capital, Recommends Buying on Pullback
-
Buyers Seem Like Deer-in-Headlights: RBC Capital; Analyst Comments on Biotech Rout
-
Vertex (VRTX) Concerns Overdone, Buy Weakness - RBC Capital
-
RBC Capital Defends Vertex Pharma (VRTX) Following Competition Speculation; Affirms at 'Outperform'
-
RBC Comments on Vertex (VRTX) Following Orkambi Briefing Docs
-
RBC Capital Comments on Vertex's (VRTX) FDA Meeting on '809 Combo
-
Vertex (VRTX) Weakness Seen as Buying Opp at RBC Capital
-
AbbVie (ABBV) /Pharmacyclics (PCYC) Deal Bullish for SMID Biotech and Big Drugs, Says RBC
-
KALYDECO sNDA Approval is Another Incremental Positive for Vertex Pharma (VRTX) - RBC Capital
-
Notable Analyst Rating Changes 11/6: (DATA) (MDLZ) (CMLP) Upgraded; (CDE) (DUK) (AEP) Downgraded
-
RBC Capital Comments on Biotechs' Irish Tax Strategies; Gilead May See Modest EPS Impact (GILD) (AMGN)
-
RBC Capital Comments on Recent Upside in Vertex (VRTX)
-
Notable Analyst Rating Changes 05/10: (TPX) (PRU) (KERX) Upgraded; (VRTX) (HGSI) (ORCL) Downgraded

